Global Atopic Dermatitis market demand 2024, Forecast To 2033
28 Feb, 2024
The atopic dermatitis market has experienced rapid growth, surging from$7.51 billion in 2023 to$8.7 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The escalation in the historic period is attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, evolution in treatment options, and advancements in research and development. Looking ahead, the atopic dermatitis market is projected to witness rapid growth, reaching$15.27 billion in 2028 with a CAGR of 15.1%. The forecasted growth can be credited to advancements in biologic therapies, immunomodulators, pediatric-specific treatments, gene therapy, precision medicine, and integration of digital health. Major trends in the forecast period encompass technological advancements in topicals, a focus on pediatric care, environmental and allergen management, and the development of precision diagnosis tools.
Global Atopic Dermatitis Market Key Driver
The high prevalence of atopic dermatitis is expected to propel the growth of the atopic dermatitis market. Atopic dermatitis, commonly known as eczema, manifests as skin dryness and itching, necessitating diagnosis and treatment. In 2021, the National Eczema Association reported 31.6 million cases of eczema in the US, affecting approximately 10% of the population, with 9.6 million cases among children under 18 years old. The pervasiveness of atopic dermatitis, especially among children, underscores the growing need for effective treatment solutions, thereby driving the atopic dermatitis market.
Get A Free Sample Of The Global Atopic Dermatitis Market ReportGlobal Atopic Dermatitis Market Segments
The global atopic dermatitis market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, Other Drug Classes
2) By Mode of Administration: Topical, Injectable, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa.
North America was the largest region in the atopic dermatitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Atopic Dermatitis Industry Players
Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited
Get The Full Global Atopic Dermatitis Market Report
Atopic Dermatitis Market Overview
Atopic dermatitis is a dermatological condition that causes dryness and itching of the skin. It is a chronic condition that progresses over time and is not spread by contact.
Atopic Dermatitis Global Market Report 2023 provides data on the global atopic dermatitis market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The atopic dermatitis market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.